NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDA
Post# of 21
(Total Views: 102)
Posted On: 10/21/2020 5:25:40 PM
NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Forms New Scientific Advisory Board
AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases using recombinant proteins, has announced the formation of a Scientific Advisory Board (“SAB”) designed to provide the company with invaluable expertise and insights. The company also announced that three leading global experts in exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis have been appointed to the board: Michael Konstan, MD; Darwin L. Conwell, MD; and Michael Wilschanski, MD. Konstan is vice dean for translational research and the Gertrude Lee Chandler Tucker Professor of Pediatrics at Case Western Reserve University School of Medicine; he is also the Austin Ricci chair in pediatric pulmonary care and research at University Hospitals Rainbow Babies and Children’s Hospital in Cleveland, Ohio. Konstan has spent his entire professional career in the care and research of people with cystic fibrosis (“CF”). Conwell is a gastroenterology physician-scientist specializing in pancreas disorders and is a professor of medicine at The Ohio State University College of Medicine where he serves as director of the Division of Gastroenterology, Hepatology and Nutrition at The Ohio State Wexner Medical Center. He is an NIH-funded physician-scientist with over 200 peer reviewed publications. The leader of numerous national and international studies of potentially new therapies in CF, Wilschanski is director of pediatric gastroenterology at Hadassah Hebrew University Medical Center. In addition, he also serves as the director of the Electrophysiology Laboratory in Hadassah where he performs in vivo and in vitro measurements of electrolyte transport, which is used diagnostically and therapeutically in CF. “We are thrilled to have this distinguished group of scientific leaders helping to guide our research and clinical development efforts as we advance our MS1819 program for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis patients,” said AzurRx CEO James Sapirstein in the press release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases using recombinant proteins, has announced the formation of a Scientific Advisory Board (“SAB”) designed to provide the company with invaluable expertise and insights. The company also announced that three leading global experts in exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis have been appointed to the board: Michael Konstan, MD; Darwin L. Conwell, MD; and Michael Wilschanski, MD. Konstan is vice dean for translational research and the Gertrude Lee Chandler Tucker Professor of Pediatrics at Case Western Reserve University School of Medicine; he is also the Austin Ricci chair in pediatric pulmonary care and research at University Hospitals Rainbow Babies and Children’s Hospital in Cleveland, Ohio. Konstan has spent his entire professional career in the care and research of people with cystic fibrosis (“CF”). Conwell is a gastroenterology physician-scientist specializing in pancreas disorders and is a professor of medicine at The Ohio State University College of Medicine where he serves as director of the Division of Gastroenterology, Hepatology and Nutrition at The Ohio State Wexner Medical Center. He is an NIH-funded physician-scientist with over 200 peer reviewed publications. The leader of numerous national and international studies of potentially new therapies in CF, Wilschanski is director of pediatric gastroenterology at Hadassah Hebrew University Medical Center. In addition, he also serves as the director of the Electrophysiology Laboratory in Hadassah where he performs in vivo and in vitro measurements of electrolyte transport, which is used diagnostically and therapeutically in CF. “We are thrilled to have this distinguished group of scientific leaders helping to guide our research and clinical development efforts as we advance our MS1819 program for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis patients,” said AzurRx CEO James Sapirstein in the press release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)